Medical Faculty, Department of Dermatology and Venereology, Ege University, Izmir, Turkey.
Medical Faculty, Department of Pathology, Ege University, Izmir, Turkey.
J Cosmet Dermatol. 2021 Aug;20(8):2645-2647. doi: 10.1111/jocd.13914. Epub 2020 Dec 28.
Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melanoma, lung, renal, head and neck, colorectal, hepatocellular cancers, and special cases of Hodgkin lymphoma.
We aimed to report a rarer cutaneous side effect of nivolumab because of the increasing uses of this agent in various cancer treatments.
We present a 48-year-old female, metastatic melanoma patient who developed plaque morphea lesion without any systemic involvement during nivolumab treatment. Plaque lesion responded well to use of topical corticosteroid and calcipotriol.
Numerous cutaneous side effects associated with nivolumab have been reported in the literature. The most common cutaneous side effects are maculopapular rash, pruritus, and vitiligo. Morphea and disorders from this spectrum reported due to PD-1 inhibitors in the literature are; morphea, sclerodermoid changes, eosinophilic fasciitis, and lichen sclerosis.
Patients who are treated by PD-1 inhibitors may be examined carefully in terms of morphea and scleroderma-like conditions although they are not as common as other cutaneous side effects.
尼伏鲁单抗是一种靶向癌症治疗药物，通过抑制抗程序性死亡受体 1（PD-1）来增强免疫反应，PD-1 是免疫反应的一个检查点。尼伏鲁单抗可用于治疗恶性黑色素瘤、肺癌、肾癌、头颈部癌、结直肠癌、肝癌和霍奇金淋巴瘤，以及特殊类型的霍奇金淋巴瘤。
由于该药物在各种癌症治疗中的应用越来越广泛，我们旨在报告一种尼伏鲁单抗较少见的皮肤副作用。
我们报告了一例 48 岁女性转移性黑色素瘤患者，在接受尼伏鲁单抗治疗期间出现斑块状硬斑病样病变，无任何系统性受累。斑块病变对局部皮质类固醇和卡泊三醇的治疗反应良好。
文献中已报道了许多与尼伏鲁单抗相关的皮肤副作用。最常见的皮肤副作用是斑丘疹、瘙痒和白癜风。文献中报道的由于 PD-1 抑制剂引起的硬斑病和该谱系的疾病包括：硬斑病、硬皮病样改变、嗜酸性筋膜炎和硬化性苔藓。
尽管 PD-1 抑制剂治疗的患者出现硬斑病和硬皮病样情况并不像其他皮肤副作用那样常见，但仍需对此类疾病进行仔细检查。
